CG Oncology
CGON
140 hedge funds and large institutions have $1.9B invested in CG Oncology in 2024 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 59 increasing their positions, 27 reducing their positions, and 17 closing their positions.
531% more call options, than puts
Call options by funds: $6.49M | Put options by funds: $1.03M
119% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 27
118% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 17
16% more funds holding
Funds holding: 121 → 140 (+19)
10.58% more ownership
Funds ownership: 77.79% → 88.38% (+11%)
9% more funds holding in top 10
Funds holding in top 10: 11 → 12 (+1)
3% less capital invested
Capital invested by funds: $1.96B → $1.9B (-$67.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$78.3M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$49.6M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$47.9M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$31.7M |
| 5 |
DC
Decheng Capital
Menlo Park,
California
|
+$30.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$52.7M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$37.5M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$19.1M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$15M |
| 5 |
PA
Perceptive Advisors
New York
|
-$10.8M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
HSBC Holdings
London,
United Kingdom
| – | -$222K | -5,792 | Closed |
|
152
Acadian Asset Management
Boston,
Massachusetts
| – | -$46K | -1,227 | Closed |
|
|
AA
153
AlphaCentric Advisors
San Juan,
Puerto Rico
| – | -$37.7K | -1,000 | Closed |
|
|
SFCL
154
Strengthening Families & Communities LLC
Boston,
Massachusetts
| – | -$37.7K | -1,000 | Closed |
|
155
Bessemer Group
Woodbridge,
New Jersey
| – | -$1K | -35 | Closed |
|
|
CPA
156
Capital Performance Advisors
Walnut Creek,
California
| – | -$38 | -1 | Closed |
|
CGON Hedge Fund Activity: Q4 2024 in Review
140 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in CG Oncology (CGON) for Q4 2024, worth a combined $1.9B — down 3.4% from $1.96B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new CGON positions and 17 closed out — a net gain of 20 holders — while 59 added to existing stakes and 27 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $78.3M. The largest seller was RA Capital Management, exiting entirely with an estimated $52.7M sold.
- 140 institutional investors held CG Oncology (CGON) as of Q4 2024, up from 121 in Q3 2024.
- Funds reported $1.9B of CG Oncology stock for Q4 2024, down 3.4% quarter-over-quarter.
- 37 funds opened new CG Oncology positions in Q4 2024 and 17 closed out, a net change of +20 holders.
- The largest CG Oncology buyer in Q4 2024 was Fidelity Investments, an estimated $78.3M added.
- The largest CG Oncology seller in Q4 2024 was RA Capital Management, an estimated $52.7M sold.
Based on aggregated 13F filings for Q4 2024.